Panic grips Ionis Pharmaceuticals investors amid bad news spree
A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua failed to meet the primary goal of a late-stage trial. The next day brought a second

